Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Amitriptyline (hydrochloride) (1) ·
Bupropion (1) ·
Citalopram (1) ·
Deschloroketamine (1) ·
Desvenlafaxine (succinate) (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Doxepin (hydrochloride) (1) ·
Ephenidine (1) ·
Escitalopram (1) ·
Eticyclidine (1) ·
Fluoxetine (1) ·
Fluvoxamine (maleate) (1) ·
Ibogaine (1) ·
Methoxetamine (1) ·
Mirtazapine (1) ·
Nitrous oxide (1) ·
Nortriptyline (hydrochloride) (1) ·
O-PCE (1) ·
Paroxetine (HCl; mesylate as Pexeva) (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Trazodone (1) ·
Venlafaxine (1) ·
Xenon (1)
brand:
None (17) ·
Celexa (1) ·
Desyrel (original IR), Oleptro (ER), Trittico (1) ·
DXM (1) ·
DXO (1) ·
Effexor XR, Effexor IR (discontinued in US, generic widely available) (1) ·
Elavil (US brand discontinued; generic widely available), Endep, Tryptizol (1) ·
Lexapro (1) ·
Luvox (US brand discontinued; generic widely available), Luvox CR, Faverin (other markets) (1) ·
Pamelor (US brand discontinued; generic widely available), Aventyl (1) ·
Paxil (IR), Paxil CR (controlled-release), Brisdelle (low-dose for menopausal vasomotor symptoms), Pexeva (paroxetine mesylate) (1) ·
Pristiq (1) ·
Prozac (1) ·
Remeron (US brand discontinued; generic widely available), Remeron SolTab (ODT) (1) ·
Sinequan (oral antidepressant, US brand discontinued), Silenor (low-dose for insomnia), Prudoxin / Zonalon (topical cream) (1) ·
Spravato (1) ·
Wellbutrin (IR, SR, XL), Zyban (smoking cessation), Aplenzin (hydrobromide salt), Forfivo XL (1)
classes: (Click arrow to add another value)
mechanism:
None (9) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
TrkB/BDNF'"`UNIQ--ref-00000040-QINU`"' '"`UNIQ--vote-00000041-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"' '''Priapism''' is a recognized rare adverse effect via α1 antagonism in penile vasculature and is the marquee counseling point for male patients'"`UNIQ--ref-00000018-QINU`"'. (1) ·
'"`UNIQ--vote-00000019-QINU`"' Therapeutic plasma-level monitoring is standard practice for TCAs given the narrow therapeutic index and the established plasma-level-efficacy correlation. CYP2D6 substrate; CPIC PGx guidance applies for dose individualization'"`UNIQ--ref-0000001A-QINU`"'. (1) ·
'"`UNIQ--vote-0000001D-QINU`"' CYP2C19 + CYP3A4 metabolism, with CPIC PGx guidance: poor CYP2C19 metabolizers have ~3-fold higher exposure and benefit from a lower starting dose; ultrarapid metabolizers may have inadequate response'"`UNIQ--ref-0000001E-QINU`"'. (2)
uses:
None (19) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (2) ·
'"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (3) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (4) ·
'"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"', '"`UNIQ--vote-00000029-QINU`"', '"`UNIQ--vote-0000002A-QINU`"' (1) ·
'"`UNIQ--vote-00000042-QINU`"', '"`UNIQ--vote-00000043-QINU`"', '"`UNIQ--vote-00000044-QINU`"' (1)
starting dose:
None (19) ·
10 mg (1) ·
10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed (1) ·
15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. '''Counterintuitive dose paradox''': lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose (1) ·
20 mg PO once daily; titrate to 40 mg/day after 1 week if tolerated. Elderly (>60) and hepatic impairment: 20 mg/day ceiling (1) ·
50 mg PO at bedtime; titrate by 50 mg every 4-7 days to clinical effect. Total daily doses >100 mg divided BID. Luvox CR: 100 mg PO once daily, may titrate to 300 mg/day (1) ·
50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine) (1) ·
Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply) (1) ·
Depression: 25 mg PO TID-QID or 75 mg at bedtime, titrate to 75-150 mg/day. Neuropathic pain: 10-25 mg at bedtime, titrate to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions, though less than amitriptyline) (1) ·
Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
Insomnia (off-label): 25-50 mg PO at bedtime, titrate to effect. Depression: 150 mg/day divided BID-TID; titrate to 400 mg/day outpatient or 600 mg/day inpatient (1) ·
MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes (1) ·
SR 150 mg PO once daily for 3 days, then 150 mg BID. XL 150 mg PO once daily for 4 days, then 300 mg once daily. Zyban (smoking cessation) 150 mg daily for 3 days, then 150 mg BID (1) ·
XR 37.5 mg PO once daily for 4-7 days, then 75 mg/day; titrate by 75 mg every ≥4 days to clinical effect. IR 25-37.5 mg BID-TID (1)
preparations:
None (19) ·
10 mg, 20 mg, 40 mg caps (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
Capsules 10, 25, 50, 75 mg; oral solution 10 mg/5 mL (1) ·
Capsules 10, 25, 50, 75, 100, 150 mg; oral concentrate 10 mg/mL; Silenor tablets 3, 6 mg; topical cream 5% (Prudoxin, Zonalon) (1) ·
ER tablets 25, 50, 100 mg (1) ·
IR tablets 10, 20, 30, 40 mg; CR tablets 12.5, 25, 37.5 mg; oral suspension 10 mg/5 mL; Brisdelle capsules 7.5 mg (1) ·
IR tablets 25, 37.5, 50, 75, 100 mg; XR capsules 37.5, 75, 150, 225 mg (1) ·
IR tablets 25, 50, 100 mg; Luvox CR capsules 100, 150 mg (1) ·
IR tablets 50, 100, 150, 300 mg; Oleptro ER tablets 150, 300 mg (1) ·
SR tablets 100, 150, 200 mg; XL tablets 150, 300 mg; IR tablets 75, 100 mg (less common); Aplenzin (bupropion hydrobromide) 174, 348, 522 mg (1) ·
Tablets 10, 20, 40 mg; oral solution 10 mg/5 mL (1) ·
Tablets 10, 25, 50, 75, 100, 150 mg (1) ·
Tablets 5, 10, 20 mg; oral solution 1 mg/mL (1) ·
Tablets 7.5, 15, 30, 45 mg; orally disintegrating tablets (SolTab) 15, 30, 45 mg (1)
fda max:
None (19) ·
'''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60 (1) ·
150 mg/day; therapeutic plasma-level monitoring recommended (target 50-150 ng/mL window) (1) ·
20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment (1) ·
225 mg/day outpatient (XR); 375 mg/day inpatient (IR divided TID); 75 mg/day in moderate hepatic impairment (1) ·
300 mg/day (depression, hospitalized); 150 mg/day outpatient; 6 mg/day for insomnia (1) ·
300 mg/day (historical hospitalized inpatient depression); 150 mg/day outpatient typical ceiling (1) ·
300 mg/day (IR or CR) (1) ·
40 mg/d (1) ·
400 mg/day outpatient; 600 mg/day inpatient (1) ·
45 mg/day (1) ·
450 mg/day; doses above this raise seizure risk steeply (1) ·
50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD) (1) ·
50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available) (1) ·
84 mg per session (1)
onset:
None (20) ·
1-2 weeks for antidepressant effect; smoking-cessation effect builds over the first 1-2 weeks (1) ·
Antidepressant effect emerges over 1-2 weeks (2) ·
Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks (1) ·
Antidepressant effect over 1-2 weeks; anxiolytic effect over 4-6 weeks (1) ·
Antidepressant effect over 1-2 weeks; full clinical effect 4-6 weeks (1) ·
OCD effect over 1-2 weeks initial, with full effect typically 6-12 weeks; among the slowest SSRIs for OCD response (1) ·
Pain and migraine prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1) ·
Sleep effect from first dose; analgesic and migraine-prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks (1) ·
Sleep effect from first dose; antidepressant effect over 1-4 weeks (2) ·
Sleep effect within 30-60 minutes; antidepressant effect over 1-2 weeks (1) ·
Within hours of first administration (1)
duration:
None (19) ·
24 hours (1) ·
24 hours (HS dosing) (4) ·
24 hours (once-daily dosing) (3) ·
24 hours (XR); 12 hours (IR) (1) ·
Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) ·
BID at higher doses (IR); once-daily (CR) (1) ·
SR ~12 hours; XL 24 hours (1) ·
Very long (1) ·
~6-8 hours (IR); 24 hours (Oleptro ER) (1)
halflife:
None (19) ·
18-44 hours'"`UNIQ--ref-00000020-QINU`"' (1) ·
1–4 days (7–15 days for norfluoxetine) (1) ·
20-40 hours'"`UNIQ--ref-00000023-QINU`"' (1) ·
27-32 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
Amitriptyline 10-50 hours (highly variable); nortriptyline active metabolite 18-44 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
Biphasic: ~3-6 hours alpha, ~5-9 hours beta'"`UNIQ--ref-0000001D-QINU`"' (1) ·
Bupropion ~21 hours; hydroxybupropion (active metabolite) ~20-37 hours'"`UNIQ--ref-00000023-QINU`"' (1) ·
Venlafaxine 5 hours; desvenlafaxine active metabolite 11 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
~11 hours'"`UNIQ--ref-0000001A-QINU`"' (1) ·
~15 hours (IR)'"`UNIQ--ref-00000023-QINU`"' (1) ·
~15 hours (parent); nordoxepin active metabolite ~30 hours'"`UNIQ--ref-00000020-QINU`"' (1) ·
~21 hours (with nonlinear pharmacokinetics from CYP2D6 autoinhibition)'"`UNIQ--ref-0000002B-QINU`"' (1) ·
~35 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
~7-12 hours (1)
bioavailability:
None (19) ·
70–90% (oral) (1) ·
Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~45%'"`UNIQ--ref-00000027-QINU`"' (1) ·
~48% intranasal (1) ·
~5-20% (extensive first-pass), highly variable between individuals'"`UNIQ--ref-00000024-QINU`"' (1) ·
~50% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~50% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~50% (oral; substantial first-pass)'"`UNIQ--ref-00000024-QINU`"' (1) ·
~53% (oral)'"`UNIQ--ref-00000024-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-0000001E-QINU`"' (1) ·
~80% (oral)'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (2)
pregnancy:
None (20) ·
'''Among the least preferred SSRIs in pregnancy.''' Observational signal for cardiac malformations (atrial and ventricular septal defects) with first-trimester exposure, and the most severe neonatal adaptation syndrome of any SSRI with third-trimester exposure'"`UNIQ--ref-0000002D-QINU`"' (1) ·
Avoid; may cause fetal harm (1) ·
Category C'"`UNIQ--ref-00000045-QINU`"' (1) ·
Limited human data; observational signals inconclusive.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; some animal cardiac signal not clearly replicated in human cohort studies; observational signals inconclusive.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; some observational signals reassuring relative to other antidepressants.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Observational signal for neonatal adaptation syndrome with late-pregnancy exposure (SNRI class effect).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Observational signal for neonatal adaptation syndrome with late-pregnancy exposure; weigh against the risks of untreated maternal depression.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Observational signal for neonatal adaptation syndrome with third-trimester exposure (SSRI class effect).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Observational signal for persistent pulmonary hypertension of the newborn (small absolute risk) and neonatal adaptation syndrome with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Older agent with substantial use experience; observational signals not clearly causal.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
TCA class signal; limited human data specific to doxepin.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
TCA class signal; limited human data specific to nortriptyline.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (19) ·
Rx, Schedule III (US). REMS program required. (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults. Not controlled'"`UNIQ--ref-00000025-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000001C-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000001F-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000022-QINU`"' (2) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000025-QINU`"' (2) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (4) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000002E-QINU`"' (1)
Showing below up to 33 results in range #1 to #33.